| Literature DB >> 32270961 |
Amer Harky1, Matthew Shaw2, Mohamad Bashir3.
Abstract
OBJECTIVE: Cardiovascular complications in Marfan patients include progressive aortic root dilation which can precipitate acute aortic dissection, ruptured aorta, severe aortic regurgitation, or all the aforementioned. Such complications can be fatal and the cause of death prior to any surgical intervention. We set out to identify the Marfan population in England and Wales and present their surgical outcomes.Entities:
Keywords: Aneurysm; Aortic Valve Insufficuency; Dissecting; Hemorrhage; Marfan Syndrome; Treatment Outcome
Mesh:
Year: 2020 PMID: 32270961 PMCID: PMC7089749 DOI: 10.21470/1678-9741-2019-0214
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Kaplan-Meier chart showing 3-year survival stratified by the most treated distal aortic segments.
Fig. 2Kaplan-Meier chart showing 3-year survival in aortic root +/- ascending aorta surgery, stratified by history of cardiac surgery.
Pre-operative characteristics.
| Marfan syndrome(n=306) | Missing data | |
|---|---|---|
| Age at operation (years) | 40 (29, 49) | 0 (0) |
| Female gender | 100 (32.7) | 0 (0) |
| Body mass index (kg/m2) | 24.2 (21.1, 27.8) | 5 (1.6) |
| Angina class IV | 9 (2.9) | 1 (0.3) |
| NYHA class ≥III | 49 (16.0) | 1 (0.3) |
| Previous Q-wave MI | 6 (2.0) | 0 (0) |
| Recent MI (within 90 days) | 4 (1.3) | 0 (0) |
| Previous PCI | 2 (0.7) | 7 (2.3) |
| Previous cardiac surgery | 25 (8.2) | 13 (4.3) |
| Diabetes (diet or insulin controlled) | 5 (1.6) | 0 (0) |
| Current smoker | 38 (12.4) | 7 (2.3) |
| History of hypertension | 116 (37.6) | 4 (1.3) |
| Creatinine >200 µmol/L | 0 (0) | 19 (6.2) |
| History of renal dysfunction | 0 (0) | 2 (0.7) |
| History of pulmonary disease | 19 (6.2) | 0 (0) |
| History of neurological disease | 10 (3.3) | 3 (1.0) |
| History of neurological dysfunction | 6 (2.0) | 2 (0.7) |
| Peripheral vascular disease | 50 (16.3) | 0 (0) |
| Non-sinus heart rhythm | 14 (4.6) | 10 (3.3) |
| Triple vessel disease | 2 (0.7) | 54 (17.7) |
| Left ventricular ejection fraction 30-50% | 34 (11.1) | 10 (3.3) |
| Left ventricular ejection fraction <30% | 7 (2.3) | 10 (3.3) |
| Intravenous nitrates or any heparin | 10 (3.3) | 0 (0) |
| Intravenous inotropes prior to anaesthesia | 3 (1.0) | 2 (0.7) |
| Pre-operative ventilation | 4 (1.3) | 3 (1.0) |
| Pre-operative cardiogenic shock | 7 (2.3) | 2 (0.7) |
Continuous variables shown as median (25th percentile, 75th percentile); categorical variables shown as frequency (%). MI=myocardial infarction; NYHA=New York Heart Association; PCI=percutaneous coronary intervention.
Operative details.
| Marfan syndrome(n=306) | Missing data | |
|---|---|---|
| Elective operation | 253 (82.7) | 0 (0) |
| Urgent operation | 21 (6.9) | 0 (0) |
| Emergency operation | 30 (9.8) | 0 (0) |
| Salvage operation | 2 (0.7) | 0 (0) |
|
| ||
| Composite valve graft and coronary reimplantation (modified Bentall or Cabroll) | 147 (48.0) | 0 (0) |
| Preservation of native valve and coronary reimplantation | 95 (31.0) | 0 (0) |
| Interposition tube graft with/without extension into the arch | 36 (11.8) | 0 (0) |
| Tube graft + separate AVR | 14 (4.6) | 0 (0) |
| Homograft root replacement | 5 (1.6) | 0 (0) |
| Aortic patch graft | 4 (1.3) | 0 (0) |
| Reduction aortoplasty | 3 (1.0) | 0 (0) |
| Sinus of Valsalva repair | 2 (0.7) | 0 (0) |
| Concomitant CABG procedure | 20 (6.5) | 13 (4.3) |
| Concomitant valve procedure | 210 (68.6) | 6 (2.0) |
| Concomitant 'other' cardiac procedure | 70 (22.9) | 12 (3.9) |
| Cardiopulmonary bypass time (mins) | 166 (128, 214) | 5 (1.6) |
| Aortic cross-clamp time (mins) | 126 (97, 161) | 6 (2.0) |
AVR=aortic valve replacement; CABG=coronary artery bypass grafting
History of previous cardiac operations
| Previous cardiac operation (n=25) | |
|---|---|
|
| |
| Valve + ascending aorta or aortic arch surgery | 12 (48.0) |
| Isolated valve | 6 (24.0) |
| Isolated ascending aorta or aortic arch surgery | 3 (12.0) |
| Valve + 'other' cardiac procedure | 2 (8.0) |
| Valve + ascending aorta or aortic arch surgery + 'other' cardiac procedure | 1 (4.0) |
| 'Other' cardiac procedure | 1 (4.0) |
|
| |
| Composite valve graft and coronary reimplantation (modified Bentall or Cabroll) | 10 (40.0) |
| Interposition tube graft with/without extension into the arch | 7 (28.0) |
| Aortic patch graft | 3 (12.0) |
| Preservation of native valve and coronary reimplantation | 2 (8.0) |
| Homograft root replacement | 1 (4.0) |
| Tube graft + separate AVR | 1 (4.0) |
| Reduction aortoplasty | 1 (4.0) |
AVR=aortic valve replacement
Post-operative outcomes.
| Marfan syndrome(n=306) | Missing data | |
|---|---|---|
| In-hospital mortality | 6 (2.0) | 0 (0) |
| All cause reoperation | 29 (9.5) | 16 (5.2) |
| Reoperation for bleeding/tamponade | 25 (8.2) | 16 (5.2) |
| Neurological complications | ||
| Paraplegia | 0 (0) | 29 (9.5) |
| CVA | 4 (1.3) | 29 (9.5) |
| TIA | 3 (1.0) | 29 (9.5) |
| Post-operative dialysis | 4 (1.3) | 22 (7.2) |
| 1-year mortality | 14/256 (5.5) | 50 (16.3) |
CVA=cerebrovascular accident; TIA=transient ischemic attack
| Abbreviations, acronyms & symbols | |
|---|---|
| AVOOMP | = Aortic valve operative outcomes in Marfan patients |
| BMI | = Body mass index |
| CCS | = Canadian Cardiovascular Society |
| COPD | = Chronic obstructive pulmonary disease |
| CVA | = Cerebrovascular accident |
| IQR | = Inter-quartile range |
| MFS | = Marfan syndrome |
| NACSA | = National Adult Cardiac Surgery Audit |
| NHS | = National Health Service |
| NICOR | = National Institute for Cardiovascular Outcomes Research |
| NYHA | = New York Heart Association |
| ONS | = Office for National Statistics |
| Authors' roles & responsibilities | |
|---|---|
| AH | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| MS | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| MB | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |